Robert Michel
Until Robert L. Michel came along and founded The Dark Intelligence Group (DIG) two decades ago, the clinical laboratory industry and the anatomic pathology profession lacked a trustworthy source for information about the management and operations of medical laboratories. From its inception in 1995, The Dark Report quickly became the “go to” source of industry intelligence, innovations in lab management, and strategic market analysis.
This excellence in reporting has earned recognition from his peers. For example, twice Michel and The Dark Report have won national awards for best investigative reporting by the Specialty Information Publishers Association. In 2005, the award was for Michel’s coverage about how the anatomic pathology condominium laboratories (pod labs) operated by urologists and gastroenterologists came to be, who operated them, and how these owners marketed the AP condo labs to other physician groups. In 2009, Michel’s award for best investigative reporting resulted from his published interviews with Quest Diagnostics Incorporated when the company admitted that, for a period of 18 months, it had been reported inaccurate Vitamin 25(OH) D results because of problems with its laboratory-developed test methodology. The Dark Report’s story was picked up by The New York Times and was in the national news cycle for several days.
In his role as Editor-in-Chief, Michel brought unique capabilities to DIG and The Dark Report. His management training and diverse business experience—along with his skills as a concise writer and analyst—proved to be a winning combination for readers of The Dark Report. For that reason, Michel’s story has many intriguing elements.
Immediately prior to founding DIG, he had served in several executive positions for Nichols Institute based in Portland, Oregon, and San Juan Capistrano, California. This was during the time that Nichols Institute was an independent public lab company with annual revenues of about $280 million (prior to its acquisition by MetPath, Inc., now Quest Diagnostics Incorporated). He traveled extensively to many of the clinical lab business units owned by Nichols Institute in different regions of the United States and played a role in formulating effective market strategies in response to the emergence of closed-panel HMOs, capitated pricing, and full-risk managed care contracts, among other successful management initiatives.
Prior to his service at Nichols Institute, Michel served at three different Fortune 100 companies. These were Procter & Gamble, Centex Corporation, and Financial Corp. of America. Each was an opportunity to master new management techniques and apply them in different industries. Between these positions, he gained experience as an entrepreneur, having founded a real estate development firm and a general contracting company in the Southeastern United States.
Robert Michel earned a Bachelor of Arts degree in Economics at the University of California, Los Angeles, where he played rugby, a sport he participated in for another 22 years. He is a native of California and grew up in Santa Ana.
Articles by Robert Michel
Upcoming Executive War College to Cover Important Lab Trends
From the Volume XXXII, No. 4 – March 10, 2025 Issue
New developments now changing the landscape in health-care and the clinical laboratory market will be addressed at the upcoming 30th Annual Executive War College on Diagnostic, Clinical Laboratory, and Pathology Management that happens on April 29-30, 20…
Why Labs Should Comply with the FDA’s Final Rule on LDTs
From the Volume XXXII, No. 3 – February 17, 2025 Issue
On April 29, 2024, the Food and Drug Administration released its final rule on regulation of laboratory developed tests (LDTs). Since then, clinical laboratories have grappled with questions surrounding compliance, while hoping that courts will step in and prevent the rule from taking effect. Now,…
Optum Adds Gestalt to Its Digital Diagnostic Suite
From the Volume XXXII, No. 3 – February 17, 2025 Issue
CEO SUMMARY: This development signals Optum’s intent to be a player in digital pathology. Its deal with Gestalt Diagnostics adds a pathology solution to Optum’s existing suite of cloud-based services for managing digital images generated by cardiology, radiology, and hematology-oncolo…
Proposed Clinical Laboratory Price Transparency Bill
From the Volume XXXII, No. 3 – February 17, 2025 Issue
IN DECEMBER, THE CLINICAL LABORATORY PRICE TRANSPARENCY ACT OF 2023 was referred to the U.S. House Ways and Means Subcommittee on Health for final approval. The bill requires labs to disclose information regarding pricing before administering services. The goal is to ensure patients better understand…
Why Labs Should Comply with FDA’s Final Rule on LDTs
From the Volume XXXII, No. 3 – February 17, 2025 Issue
CEO SUMMARY: Even as lawsuits challenging the Laboratory Developed Test (LDT rule) issued by the federal Food and Drug Administration (FDA) progress in federal court, clinical labs performing LDTs face an interesting decision. Should they invest the staff time and money to comply with the…
Quest Diagnostics, Labcorp Issue Q4 and Full Year 2024 Earnings
From the Volume XXXII, No. 3 – February 17, 2025 Issue
LAB ACQUISITIONS IN 2024 WERE A CONTRIBUTING FACTOR TO REVENUE GROWTH at the nation’s two biggest clinical laboratory companies. This was reflected in the fourth quarter and full year 2024 earnings reports issued by Labcorp and Quest Diagnostics. Here are recently …
Grim Realities Drive Payer Behavior with Lab Test Claims
From the Volume XXXII, No. 3 – February 17, 2025 Issue
February 17, 2025, Intelligence: Late-Breaking Lab News
From the Volume XXXII, No. 3 – February 17, 2025 Issue
To implement a corporate restructuring, Becton Dickinson (BD) announced on Feb. 5, 2025, that it would proceed to “separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD.” The company plans to complete this action by the end of 2025. Clinical laboratori…
Mayo Clinic’s Ambitious Digital Pathology Initiative
From the Volume XXXII, No. 3 – February 17, 2025 Issue
CEO SUMMARY: It’s the latest example of an academic medical center moving to develop its own digital pathology solutions. This collaboration involves Mayo Clinic, Nvidia, and Aignostics. The three will work together to use digital pathology images and patient data from Mayo Clinic and C…
Optum Adds Gestalt to Its Digital Diagnostic Suite
From the Volume XXXII, No. 3 – February 17, 2025 Issue
CEO SUMMARY: This development signals Optum’s intent to be a player in digital pathology. Its deal with Gestalt Diagnostics adds a pathology solution to Optum’s existing suite of cloud-based services for managing digital images generated by cardiology, radiology, and hematology-oncolo…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized